Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension

Journal of Viral Hepatitis

Volumn 24, Issue 10, 2017, Pages 823-831

  Afdhal, N ^a   Everson, G T ^b   Calleja, J L ^c   McCaughan, G W ^d   Bosch, J ^e,f   Brainard, D M ^g   McHutchison, J G ^g   De Oertel, S ^g   An, D ^g   Charlton, M ^h   Reddy, K R ⁱ   Asselah, T ^j   Gane, E ^k   Curry, M P ^a   Forns, X ^e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f UNIVERSITY OF BERN   (Switzerland)

^g GILEAD SCIENCES   (United States)

^h INTERMOUNTAIN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j INSERM   (France)

^k UNIVERSITY OF AUCKLAND   (New Zealand)

more..

Author keywords

advanced liver disease; cirrhosis; decompensated cirrhosis; direct acting antivirals; hepatic venous pressure gradient; portal hypertension

Indexed keywords

RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASCITES; ASTHENIA; BACTEREMIA; CHILD PUGH SCORE; CHOLECYSTITIS; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; ESOPHAGUS VARICES; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATIC VENOUS PRESSURE GRADIENT; HUMAN; INSOMNIA; JAUNDICE; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PORTAL HYPERTENSION; POSTOPERATIVE HEMORRHAGE; PRESSURE GRADIENT; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; SWELLING; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRAL CLEARANCE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; LIVER VEIN; MIDDLE AGED; PATHOPHYSIOLOGY; PORTAL VEIN BLOOD PRESSURE; TIME FACTOR; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATIC VEINS; HEPATITIS C; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTAL PRESSURE; RNA, VIRAL; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS; VIRAL LOAD;

EID: 85017462786     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12706     Document Type: Article

References (15)

1. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488.
2. Garcia-Tsao G, Friedman S, Iredale J, et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445-1449.
3. Albilllos A, Garcia-Tsao G. Classification of cirrhosis: the clinical use of HVPG measurements. Dis Markers. 2011;31:121-128.
4. Suk KT. Hepatic venous pressure gradient: clinical use in chronic liver disease. Clin Mol Hepatol. 2014;20:6-14.
5. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902-908.
6. Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol. 2006;101:2269-2274.
7. Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5:932-937.
8. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39:280-282.
9. Bosch J, Garcia-Pagán JC, Berzigotti A, et al. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis. 2006;26:348-362.
10. Ripoll C, Bañares R, Rincón D, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology. 2005;42:793-801.
11. Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923-928.
12. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
13. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618-2628.
14. Lens S, Rincón D, García-Retortillo M, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol. 2015;13:1846-1853.e1.
15. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-697.